LT2877467T - 2-(azaindol-2-il)benzimidazolai, kaip pad4 inhibitoriai - Google Patents

2-(azaindol-2-il)benzimidazolai, kaip pad4 inhibitoriai

Info

Publication number
LT2877467T
LT2877467T LTEP12740581.9T LT12740581T LT2877467T LT 2877467 T LT2877467 T LT 2877467T LT 12740581 T LT12740581 T LT 12740581T LT 2877467 T LT2877467 T LT 2877467T
Authority
LT
Lithuania
Prior art keywords
azaindol
benzimidazoles
pad4 inhibitors
pad4
inhibitors
Prior art date
Application number
LTEP12740581.9T
Other languages
English (en)
Lithuanian (lt)
Inventor
Stephen John Atkinson
Michael David Barker
Matthew Campbell
Hawa Diallo
Clement Douault
Neil Stuart Garton
John Liddle
Robert John Sheppard
Ann Louise Walker
Christopher WELLAWAY
David Matthew Wilson
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of LT2877467T publication Critical patent/LT2877467T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP12740581.9T 2012-07-26 2012-07-26 2-(azaindol-2-il)benzimidazolai, kaip pad4 inhibitoriai LT2877467T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/064649 WO2014015905A1 (en) 2012-07-26 2012-07-26 2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors

Publications (1)

Publication Number Publication Date
LT2877467T true LT2877467T (lt) 2017-01-10

Family

ID=49996626

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12740581.9T LT2877467T (lt) 2012-07-26 2012-07-26 2-(azaindol-2-il)benzimidazolai, kaip pad4 inhibitoriai

Country Status (22)

Country Link
US (4) US9127003B2 (enExample)
EP (1) EP2877467B1 (enExample)
JP (1) JP6063567B2 (enExample)
KR (1) KR101916443B1 (enExample)
CN (1) CN104470919B (enExample)
AU (1) AU2012386257B2 (enExample)
BR (1) BR112015001545B1 (enExample)
CA (1) CA2879341C (enExample)
CY (1) CY1118524T1 (enExample)
DK (1) DK2877467T3 (enExample)
ES (1) ES2609126T3 (enExample)
HR (1) HRP20161530T1 (enExample)
HU (1) HUE033294T2 (enExample)
IN (1) IN2014KN02935A (enExample)
LT (1) LT2877467T (enExample)
PL (1) PL2877467T3 (enExample)
PT (1) PT2877467T (enExample)
RS (1) RS55684B1 (enExample)
RU (1) RU2611010C2 (enExample)
SI (1) SI2877467T1 (enExample)
SM (2) SMT201700052T1 (enExample)
WO (1) WO2014015905A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA033680B1 (ru) * 2015-05-21 2019-11-15 Glaxosmithkline Ip Dev Ltd Производные бензоимидазола в качестве ингибиторов pad4
AR107030A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores aza-bencimidazol de pad4
AR107032A1 (es) 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
EA201891910A1 (ru) 2016-02-23 2019-02-28 Падлок Терапьютикс, Инк. Гетероарильные ингибиторы pad4
CN107188867A (zh) * 2016-03-14 2017-09-22 中国科学院天津工业生物技术研究所 精氨酸脱亚氨酶4的抑制剂
US10703741B2 (en) 2016-07-27 2020-07-07 Padlock Therapeutics, Inc. Covalent inhibitors of PAD4
JP7118951B2 (ja) 2016-09-12 2022-08-16 パドロック・セラピューティクス・インコーポレイテッド Pad4のヘテロアリール阻害剤
WO2018102262A1 (en) * 2016-12-02 2018-06-07 University Of Massachusetts Inhibitors of protein arginine deiminases (pads) and methods of preparation and use thereof
CN108689946B (zh) * 2017-04-12 2022-10-18 中国科学院上海药物研究所 2-取代硫基乙酰胺类化合物及其制备方法和应用
IL273428B2 (en) * 2017-09-22 2023-09-01 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
EP3697785B1 (en) * 2017-10-18 2022-12-28 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
JP7279057B6 (ja) 2017-11-06 2024-02-15 ジュビラント プローデル エルエルシー Pd1/pd-l1活性化の阻害剤としてのピリミジン誘導体
SG11202004537UA (en) 2017-11-24 2020-06-29 Jubilant Episcribe Llc Heterocyclic compounds as prmt5 inhibitors
JP2021515043A (ja) * 2018-02-26 2021-06-17 南京薬捷安康生物科技有限公司Nanjing Transthera Biosciences Co., Ltd. ペプチジルアルギニンデイミナーゼ阻害剤及びその使用
US11529341B2 (en) 2018-03-13 2022-12-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
WO2019236884A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2020033488A1 (en) * 2018-08-08 2020-02-13 Bristol-Myers Squibb Company Substituted benzimidazoles as pad4 inhibitors
US11524959B1 (en) 2018-08-08 2022-12-13 Bristol-Myers Squibb Company Indole and azaindole inhibitors of pad enzymes
JP7434281B2 (ja) * 2018-08-08 2024-02-20 ブリストル-マイヤーズ スクイブ カンパニー Pad酵素のベンズイミダゾール阻害剤
US11981680B2 (en) 2018-08-08 2024-05-14 Bristol-Myers Squibb Company Substituted thienopyrroles as PAD4 inhibitors
CN109369513B (zh) * 2018-11-20 2020-08-25 都创(上海)医药科技有限公司 一种fbdd常用分子片段的制备方法
WO2020132045A1 (en) 2018-12-19 2020-06-25 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
EP3994128A4 (en) * 2019-07-03 2022-12-07 University of Massachusetts INHIBITORS OF PROTEIN ARGININE DEIMINASE 1, AND PROCESSES FOR THEIR PREPARATION AND USE
WO2021057910A1 (zh) * 2019-09-27 2021-04-01 南京药捷安康生物科技有限公司 肽酰精氨酸脱亚胺酶抑制剂及其用途
EP4100405A1 (en) * 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Macrocyclic pad4 inhibitors useful as immunosuppressant
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環pad4抑制劑
CN111265526B (zh) * 2020-04-09 2021-03-19 黑龙江中医药大学 一种治疗胃癌的药物及其制备方法
MX2022013615A (es) 2020-04-30 2022-11-16 Gilead Sciences Inc Inhibidores de macrociclo de peptidilarginina deiminasas.
KR20230093251A (ko) 2020-09-10 2023-06-27 프리시릭스 엔.브이. Fap에 대한 항체 단편
KR20230069162A (ko) 2020-09-18 2023-05-18 스미토모 파마 가부시키가이샤 아민 유도체
WO2022140428A2 (en) 2020-12-22 2022-06-30 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
TW202241884A (zh) 2020-12-22 2022-11-01 美商基利科學股份有限公司 肽基精胺酸去亞胺酶之抑制劑
WO2023083365A1 (en) 2021-11-15 2023-05-19 Qilu Regor Therapeutics Inc. Pad4 inhibitors and use thereof
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
EP4518911A1 (en) 2022-05-02 2025-03-12 Precirix N.V. Pre-targeting
WO2023230609A1 (en) * 2022-05-26 2023-11-30 Celgene Corporation Heterocyclic pad4 inhibitors
EP4622977A1 (en) * 2022-11-24 2025-10-01 Helios Huaming Biopharma Co., Ltd. Selenium containing heterocycle compounds and use thereof
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570439B2 (en) 1983-03-28 1988-03-17 Compression Labs, Inc. A combined intraframe and interframe transform coding system
CN1217654C (zh) 1995-04-14 2005-09-07 史密丝克莱恩比彻姆公司 舒喘宁的计定剂量吸入器
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
HUP0200355A3 (en) * 1998-09-18 2004-07-28 Abbott Gmbh & Co Kg 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
DE60018782T2 (de) * 1999-10-19 2006-04-06 Merck & Co., Inc. Tyrosin kinase inhibitoren
WO2001047922A2 (en) 1999-12-24 2001-07-05 Aventis Pharma Limited Azaindoles
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
WO2005044354A1 (en) 2003-11-03 2005-05-19 Glaxo Group Limited A fluid dispensing device
MXPA06005578A (es) 2003-11-17 2006-08-11 Pfizer Prod Inc Compuestos de pirrolopirimidina utiles en el tratamiento del cancer.
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US7429611B2 (en) * 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
EP2205085A1 (en) * 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
US20090311217A1 (en) 2008-05-28 2009-12-17 Wyeth 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
RU2011106786A (ru) * 2008-07-23 2012-08-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы пиразолопиридинкиназы
AU2010233917B2 (en) 2009-04-02 2015-07-02 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
WO2010118208A1 (en) 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer

Also Published As

Publication number Publication date
SI2877467T1 (sl) 2017-02-28
US9518054B2 (en) 2016-12-13
US20150175600A1 (en) 2015-06-25
AU2012386257B2 (en) 2016-09-08
RS55684B1 (sr) 2017-07-31
IN2014KN02935A (enExample) 2015-05-08
US20160009716A1 (en) 2016-01-14
CA2879341C (en) 2019-06-11
US20170119750A1 (en) 2017-05-04
KR101916443B1 (ko) 2018-11-08
AU2012386257A1 (en) 2015-03-12
HRP20161530T1 (hr) 2017-02-10
HUE033294T2 (en) 2017-11-28
US9127003B2 (en) 2015-09-08
BR112015001545B1 (pt) 2022-07-05
BR112015001545A2 (pt) 2017-07-04
DK2877467T3 (en) 2017-02-13
WO2014015905A1 (en) 2014-01-30
JP2015522628A (ja) 2015-08-06
KR20150038438A (ko) 2015-04-08
CA2879341A1 (en) 2014-01-30
US10039755B2 (en) 2018-08-07
CY1118524T1 (el) 2017-07-12
PT2877467T (pt) 2017-01-02
US20180161316A1 (en) 2018-06-14
US9833449B2 (en) 2017-12-05
CN104470919B (zh) 2016-07-06
EP2877467B1 (en) 2016-11-02
EP2877467A1 (en) 2015-06-03
RU2611010C2 (ru) 2017-02-17
PL2877467T3 (pl) 2017-08-31
RU2014152456A (ru) 2016-09-20
ES2609126T3 (es) 2017-04-18
SMT201700052T1 (it) 2017-03-08
CN104470919A (zh) 2015-03-25
JP6063567B2 (ja) 2017-01-18
SMT201700052B (it) 2017-03-08

Similar Documents

Publication Publication Date Title
PL2877467T3 (pl) 2-(azaindolo-2-ylo)benzoimidazole jako inhibitory pad4
IL239193A0 (en) New Benzimidazole Derivatives as Kinase Inhibitors
HUE044300T2 (hu) 3-amino-cikloalkil-vegyületek, mint ROR-GAMMA-T inhibitorok és alkalmazásuk
ZA201501009B (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
EP2832734A4 (en) HETEROCYCLIC COMPOUND
ZA201504980B (en) Heterocyclic compound
IL237475A0 (en) Pyrlotriazinone derivatives as pi3k inhibitors
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
ZA201406225B (en) Thiadiazolidinediones as gsk-3 inhibitors
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
PT2912041T (pt) Inibidores de bace
EP2847201A4 (en) 6-oxo-purin-phosphoribosyl INHIBITORS
EP2866893A4 (en) HETEROCYCLIC GUANIDINE F1FO ATPASE INHIBITORS
EP2847186A4 (en) SUBSTITUTED AMINOCHINAZOLINES USE AS CHINESE HEMMER
IL235919A0 (en) inhibitors of fbxo3